Prevalence of Mutations in a Diverse Cohort of 3162 Women Tested via the Same Multigene Cancer Panel in a Managed Care Health Plan - PubMed

Prevalence of Mutations in a Diverse Cohort of 3162 Women Tested via the Same Multigene Cancer Panel in a Managed Care Health Plan - PubMed

Prevalence of Mutations in a Diverse Cohort of 3162 Women Tested via the Same Multigene Cancer Panel in a Managed Care Health Plan

Mónica Alvarado 1, George E Tiller 1, Joanie Chung 2, Reina Haque 3

Affiliations 

• PMID: 32096056
 
• DOI: 10.1007/s12687-020-00456-6

Abstract

Advances in gene sequencing of mutations related to hereditary cancers have enabled expansion of this testing to patients cared for in community clinics. Our goal was to report on the prevalence of pathogenic/likely pathogenic variants (PV/LPV) and the distribution of mutations by cancer history in a diverse cohort. We evaluated 3162 women in a large non-profit health plan who were referred for cancer genetic counseling and tested them via the same multigene cancer panel. We examined the pathogenic variant/likely pathogenic variant (PV/LPV) prevalence for 20 genes by clinical factors, demographics, and personal or family cancer history. We calculated adjusted odds ratios for the association between race/ethnicity and mutation results. The majority of women (65.4%) were referred post-breast or ovarian cancer diagnosis. The overall prevalence of any PV/LPV result was 11.7%. Overall, nearly 5.4% had BRCA1/2 mutations, while 6.3% had at least one mutation in non-BRCA genes. In the subset with any PV/LPV result, 55.0% of the total mutations were in non-BRCA genes. The distribution of mutations was similar in those with or without a personal cancer history. Latina women were somewhat less likely to have mutations in non-BRCA genes implicated with breast cancer (OR = 0.55, 95% CI 0.36-0.87). Given that 55.0% of the PV/LPV results were in genes other than BRCA1/2, regardless personal or family cancer history, the study suggests that multigene cancer panel testing may be appropriate for detecting germline mutations in a high-risk cohort in a managed care or public health setting.

Keywords: BRCA; Breast cancer; Cancer gene panel testing; Mutations; Population based.

Similar articles

• Preferences for Multigene Panel Testing for Hereditary Breast Cancer Risk Among Ethnically Diverse BRCA-uninformative Families

  B Vicuña et al. J Community Genet 9 (1), 81-92. Jan 2018. PMID 28971318.

  Until recently, genetic testing for hereditary breast cancer has primarily focused on pathogenic variants in the BRCA1 and BRCA2 (BRCA) genes. However, advances in DNA se …
• Genetic Tests for Breast and Ovarian Cancer [Internet]

  LK Juvet et al. Feb 2008. PMID 29319983. - Review

  Background Breast cancer is the most commonly diagnosed cancer in women. In 2005, there were about 3000 incident cases of breast cancer in Norway. Ovarian canc …
• Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment

  A Desmond et al. JAMA Oncol 1 (7), 943-51. Oct 2015. PMID 26270727.

  In a clinically representative cohort, multigene panel testing for HBOC risk assessment yielded findings likely to change clinical management for substantially more patie …
• Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and Has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer

  NS Kapoor et al. Ann Surg Oncol 22 (10), 3282-8. Oct 2015. PMID 26219241. - Clinical Trial

  Multigene panel testing detects pathogenic BRCA1/2 mutations at equivalent rates as limited testing and increases the diagnostic yield. Panel testing increases the VUS ra …
• Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility [Internet]

  HD Nelson et al. Sep 2005. PMID 20722133. - Review

  The evidence base for genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility as a screening strategy is limited by lack of …